WEKO3
アイテム
Effectiveness of therapy with low-dosage masitinib on pulmonary hypertension in dogs: a pilot study
https://repository.lib.tottori-u.ac.jp/records/2001702
https://repository.lib.tottori-u.ac.jp/records/20017029d75fae8-ea32-4239-ad5f-ccd741e680e2
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
avb_91(4)_363.pdf (433.1 KB)
|
.png)
|
| Item type | デフォルトアイテムタイプ（フル）(1) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 公開日 | 2025-02-12 | |||||||||||||
| タイトル | ||||||||||||||
| タイトル | Effectiveness of therapy with low-dosage masitinib on pulmonary hypertension in dogs: a pilot study | |||||||||||||
| 言語 | en | |||||||||||||
| 作成者 |
Sahashi,Yu
× Sahashi,Yu
× 日笠,喜朗
WEKO
4880
|
|||||||||||||
| 主題 | ||||||||||||||
| 言語 | en | |||||||||||||
| 主題Scheme | Other | |||||||||||||
| 主題 | Chronic heart failure | |||||||||||||
| 主題 | ||||||||||||||
| 言語 | en | |||||||||||||
| 主題Scheme | Other | |||||||||||||
| 主題 | tyrosine kinase inhibitor | |||||||||||||
| 主題 | ||||||||||||||
| 言語 | en | |||||||||||||
| 主題Scheme | Other | |||||||||||||
| 主題 | pulmonary arterial pressure | |||||||||||||
| 主題 | ||||||||||||||
| 言語 | en | |||||||||||||
| 主題Scheme | Other | |||||||||||||
| 主題 | right ventricular function | |||||||||||||
| 内容記述 | ||||||||||||||
| 内容記述タイプ | Other | |||||||||||||
| 内容記述 | The purpose of this pilot study was to assess the efficacy of long-term masitinib therapy at low doses on echocardiographic, cardiovascular, haematological, and blood biochemical indicators, as well as clinical symptoms in dogs with pulmonary hypertension (PH) caused by advanced chronic degenerative mitral valve disease or heartworm disease. Seven client-owned dogs with severe PH were recruited prospectively and given low-dose masitinib orally, 3 mg/kg body weight (approximately one-fourth of the recommended antineoplastic dosage), q24h, for 123–928 days. Examinations were performed prior to masitinib administration, as well as 1, 2, 3, 6, and 12 months later. At 1–12 months, low-dose masitinib significantly reduced systolic pulmonary arterial pressure (P < 0.05 or 0.01) and dramatically improved clinical symptoms. Low-dose masitinib treatment improved right ventricular function indicators such as right atrium/aorta ratio, maximum tricuspid regurgitation velocity, right ventricular Tei index, and tricuspid annular plane systolic excursion, without worsening left ventricular function indicators. These findings suggest that low-dose masitinib may be effective as an adjunctive therapeutic for chronic heart failure in dogs with PH and may increase the survival of PH dogs. | |||||||||||||
| 言語 | en | |||||||||||||
| 出版者 | ||||||||||||||
| 出版者 | University of Veterinary and Pharmaceutical Sciences | |||||||||||||
| 言語 | en | |||||||||||||
| 日付 | ||||||||||||||
| 日付 | 2022-10-24 | |||||||||||||
| 日付タイプ | Issued | |||||||||||||
| 言語 | ||||||||||||||
| 言語 | eng | |||||||||||||
| 資源タイプ | ||||||||||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||||||||||
| 資源タイプ | journal article | |||||||||||||
| 出版タイプ | ||||||||||||||
| 出版タイプ | VoR | |||||||||||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||||||||||
| 関連情報 | ||||||||||||||
| 関連タイプ | isIdenticalTo | |||||||||||||
| 識別子タイプ | DOI | |||||||||||||
| 関連識別子 | https://doi.org/10.2754/avb202291040363 | |||||||||||||
| 収録物識別子 | ||||||||||||||
| 収録物識別子タイプ | PISSN | |||||||||||||
| 収録物識別子 | 18017576 | |||||||||||||
| 収録物名 | ||||||||||||||
| 収録物名 | Acta Veterinaria Brno | |||||||||||||
| 言語 | en | |||||||||||||
| 巻 | ||||||||||||||
| 巻 | 91 | |||||||||||||
| ページ数 | ||||||||||||||
| ページ数 | 11 | |||||||||||||
| 開始ページ | ||||||||||||||
| 開始ページ | 363 | |||||||||||||
| 終了ページ | ||||||||||||||
| 終了ページ | 373 | |||||||||||||
| 書誌情報 |
en : Acta Veterinaria Brno 巻 91, p. 363-373, ページ数 11, 発行日 2022-10-24 |
|||||||||||||
| アクセス権 | ||||||||||||||
| アクセス権 | open access | |||||||||||||
| アクセス権URI | http://purl.org/coar/access_right/c_abf2 | |||||||||||||
| 権利情報 | ||||||||||||||
| 言語 | en | |||||||||||||
| 権利情報 | This work is licensed under a Creative Commons Attribution 4.0 International License. | |||||||||||||
